COMP <GO>
IMCR vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Immunocore Holdings plc (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: IMCR 2
— ABBV 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ABBV
LAST: $31.27 (-4.11%) • MKT CAP: $1.61B
balance-sheet
1.40
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMCR VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMCR | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 70.20% | +25.80 | IMCR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.93% | 3.47% | -4.40 | ABBV | /fcf-yield <GO> |
| Operating Margin | -11.30% | 24.60% | -35.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -8.90% | 6.90% | -15.80 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 29.00% | 8.60% | +20.40 | IMCR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.40 | 5.33 | -3.93 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.8 | 65.1 | -14.30 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.61B | $513.86B | -$512.25B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMCR REV | ABBV REV | IMCR GROSS % | ABBV GROSS % | IMCR FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $400.0M | $61.16B | 98.0% | 70.2% | -$15.1M | $17.82B |
| FY 2024 | $310.2M | $56.33B | 98.0% | 70.0% | $20.9M | $17.83B |
| FY 2023 | $249.4M | $54.32B | — | — | $2.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMCR // BETA —
ABBV // BETA 1.15